Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain penetrant, and selective inhibitor of the mutant Isocitrate dehydrogenase 1 (IDH1) (IC50: 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively).
Molecular Weight:
354.79
Purity:
98.57%
CAS Number:
[1887014-12-1]
Formula:
C18H15ClN4O2
Target:
Isocitrate Dehydrogenase (IDH)|||Dehydrogenase
T16384
* VAT and and shipping costs not included. Errors and price changes excepted
